RC48 in Combination With AK104 and Bevacizumab in OCCC

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study ID
NCT06540729
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Ovary Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)

Key Dates

First listed
Aug 6, 2024
Start date
Sep 24, 2024
Status verified
Aug 2024
Primary completion
Aug 1, 2028
Completion
Aug 1, 2030

Study Design

Enrollment
39 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer

Primary Outcome Measure

Objective Response Rate [ Time Frame: 2 years ]

Central Contacts

Related Studies